Neoadjuvant Ontruzant (SB3) in Patients With HER2-positive Early Breast Cancer: An Open-Label (NeoON)
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Breast Neoplasms|Breast Cancer Female|HER2-positive Breast Cancer
Interventions: DRUG: Ontruzant|DRUG: Chemotherapy|DRUG: Pertuzumab
Sponsor: Institut fuer Frauengesundheit
Collaborators: Samsung Bioepis Co., Ltd.